Literature DB >> 24065784

Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic.

Scott J Edwards1, Rick Abbott, Jonathan Edwards, Michael LeBlanc, George Dranitsaris, Jennifer Donnan, Kara Laing, Maria A Whelan, Neil J MacKinnon.   

Abstract

The primary goal of seamless care is improved patient outcomes and improved standards of care for patients with cancer. The pharmacy service of the Newfoundland Cancer Treatment and Research Foundation conducted a randomized control study that measured clinical and humanistic outcomes of a pharmacist-directed seamless care program in an ambulatory oncology clinic. This article focuses on the intervention group, particularly the identification of drug-related problems (DRPs) and utilization of health care services as well the satisfaction of 3 types of health professionals with the services provided by the pharmacist-directed seamless care program. Overall, the seamless care pharmacist (SCP) identified an average of 3.7 DRPs per intervention patient; the most common DRP reported was a patient not receiving or taking a drug therapy for which there is an indication. The SCP identified more DRPs in patients receiving adjuvant treatment compared to those receiving palliative treatment. On average, family physicians, oncology nurses, and hospital pharmacists were satisfied with the SCP intervention indicating that they agreed the information collected and distributed by the SCP was useful to them. Pharmacist-directed seamless care services in an ambulatory oncology clinic have a significant impact on clinical outcomes and processes of patient care. The presence of a SCP can help identify and resolve DRPs experienced by patients in an outpatient oncology clinic, ensuring that patients are receiving the highest standard of care.

Entities:  

Keywords:  drug-related problems; medication reconciliation; oncology pharmacists; pharmaceutical care; seamless care

Mesh:

Year:  2013        PMID: 24065784     DOI: 10.1177/0897190013504954

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  7 in total

Review 1.  The need for community pharmacists in oncology outpatient care: a systematic review.

Authors:  Johannes Thoma; Romána Zelkó; Balázs Hankó
Journal:  Int J Clin Pharm       Date:  2016-04-07

Review 2.  Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer.

Authors:  S Chia; S Gandhi; A A Joy; S Edwards; M Gorr; S Hopkins; J Kondejewski; J P Ayoub; N Califaretti; D Rayson; S F Dent
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

3.  Network analysis of drug-related problems in hospitalized patients with hematologic malignancies.

Authors:  Myeong Gyu Kim; Chae Reen Jeong; Hyun Jee Kim; Jae Hyun Kim; Yun-Kyoung Song; Kyung Im Kim; Eunhee Ji; Sung-Soo Yoon; Youngil Koh; Yoon-Sook Cho; In-Wha Kim; Jung Mi Oh
Journal:  Support Care Cancer       Date:  2018-02-27       Impact factor: 3.603

Review 4.  Pharmacist services for non-hospitalised patients.

Authors:  Mícheál de Barra; Claire L Scott; Neil W Scott; Marie Johnston; Marijn de Bruin; Nancy Nkansah; Christine M Bond; Catriona I Matheson; Pamela Rackow; A Jess Williams; Margaret C Watson
Journal:  Cochrane Database Syst Rev       Date:  2018-09-04

5.  Impact of informational and relational continuity for people with palliative care needs: a mixed methods rapid review.

Authors:  Briony F Hudson; Sabine Best; Patrick Stone; Thomas Bill Noble
Journal:  BMJ Open       Date:  2019-05-29       Impact factor: 2.692

6.  2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard.

Authors:  Emily Mackler; Eve M Segal; Benyam Muluneh; Kate Jeffers; Jenna Carmichael
Journal:  J Oncol Pract       Date:  2019-03-12       Impact factor: 3.840

7.  The oncology pharmacist as part of the palliative treatment team.

Authors:  Mirjam Crul; Piter Oosterhof
Journal:  Int J Pharm Pract       Date:  2019-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.